IP Group portfolio company Microbiotica reports promising trial results in ulcerative colitis

Microbiotica's Phase 1b COMPOSER-1 trial of oral live biotherapeutic MB310 met primary and secondary endpoints, showing a 63.2% clinical remission rate versus 30% for placebo in 29 adults with mild-to-moderate ulcerative colitis, with rapid engraftment of its eight-strain consortium, improved histology and reduced faecal calprotectin and a strong safety profile. IP Group, which holds a 16.7% stake in Microbiotica valued at £13.9m as of last June, said the company plans to advance MB310 into a Phase 2/3 combination trial and is exploring partnering and financing options to fund the programme.

Analysis

Market structure: MB310’s Phase 1b signal (63.2% vs 30% placebo, n=29) lifts the clinical and M&A optionality of microbiome therapeutics but does not materially disrupt incumbent ulcerative colitis (UC) franchises yet. Winners: Microbiotica (private), IP Group (IPO.L) as a minority holder, and large pharmas looking for bolt‑on inflammation assets; losers: small UC developers with weaker data and manufacturers unable to scale live biotherapeutics. Expect limited immediate pricing power in UC until larger combo trials show superiority versus established biologics; market share shifts are incremental over 12–36 months, not instant.

Risk assessment: Key tail risks are Phase 2/3 non‑replication, regulatory concerns about live biotherapeutic manufacturing and strain stability, and financing dilution if partners are not secured—each could erase >50% of implied value. Immediate (days) risk is modest volatility in IPO.L on headlines; short term (3–6 months) risk centers on deal/financing announcements; long term (12–36 months) outcome risk hinges on Phase 2/3 efficacy and payer acceptance. Hidden dependencies include cold‑chain logistics, combination‑therapy labeling, and IP coverage for strain consortiums.

Trade implications: Tactical plays favor small, event‑driven exposure to IP Group (IPO.L) and options to cap downside—expect most upside on a partner/licensing deal within 3–12 months. Use relative trades to isolate idiosyncratic upside (long IPO.L, short broad biotech ETF IBB) to hedge sector beta. Catalysts to watch that would justify scaling positions: signed partner/term sheet, announced Phase 2/3 start, or GMP manufacturing agreement within 90–180 days.

Contrarian angles: Consensus will over‑interpret Phase 1b remission as de‑risking; with n=29 external validity is low and placebo remission (30%) is unusually high—statistical volatility is large. Conversely, if MB310 shows durable remission in combination with standard therapies, the asset could be acquired at 3–6x current implied private value, creating asymmetric upside. Avoid binary thinking: size positions for optionality (small, liquid) until >=150 patient Phase 2 signals reduce failure probability materially.

Key Decisions for Investors

• Establish a 1–2% portfolio long position in IP Group (LSE: IPO.L) within 7 trading days to gain exposure to Microbiotica upside; set a 12‑month target +40% on a licensing/partner announcement and a hard stop loss at -25% from entry to limit dilution/regulatory risk.
• Buy a 9–12 month call spread on IPO.L (buy ATM call / sell 15–25% OTM call) sized to represent 0.5% portfolio delta to capture partner/Phase‑2 initiation upside while capping premium; roll or close if no material partner news in 180 days.
• Implement a pair trade: long IPO.L (1.0% portfolio) and short IBB (iShares Nasdaq Biotechnology ETF) 0.5% portfolio to neutralise sector beta; reassess after 90–180 days or upon Phase 2 start/partnering news.
• Do NOT increase exposure until one of the following catalysts occurs: (a) signed partnering/financing term sheet within 90 days, (b) Phase 2/3 trial initiation announced within 180 days, or (c) third‑party GMP manufacturing agreement signed; any of these justify scaling to 3–5% position size.
• Monitor specific triggers over next 30–60 days: announcement of partner discussions, financing round size/valuation (threshold: non‑dilutive partner or financing <£50m preferred), and any regulatory feedback; act to add only if at least one threshold is met.